



14 June 2021

# Drug Discovery Symposium on Targeted therapeutic approaches against cancer and ageing

International Virtual meeting

Institute of Chemical Biology | National Hellenic Research Foundation

## Invited Speakers

- Dr. Gideon E. Bollag**, CEO, Plexikon Inc, Berkeley, CA, USA
- Prof. Mark Bradley**, The University of Edinburgh, Edinburgh, UK
- Prof. Ian Collins**, Institute for Cancer Research, London, UK
- Prof. Maria Paola Costi**, University of Modena and Reggio Emilia, Italy
- Prof Nissim Garti**, Hebrew University of Jerusalem, Israel
- Dr Maria Koufaki**, National Hellenic Research Foundation, Athens, Greece
- Prof. Stefano Mangani**, University of Siena, Siena, Italy
- Dr. George N. Pavlakis**, National Cancer Institute, Frederick, MD, USA
- Dr Alex Pintzas**, National Hellenic Research Foundation, Athens, Greece
- Dr. Chris Torrance**, CEO, Phoremost Ltd, Cambridgeshire, UK
- Dr. Valerie Vanhooren**, CEO ONA Therapeutics, Barcelona, Spain

Register here: [https://zoom.us/webinar/register/WN\\_NAb9I4g6RO6FXmwBt6JNVg](https://zoom.us/webinar/register/WN_NAb9I4g6RO6FXmwBt6JNVg)  
No registration fees

Information: [amilitsi@iee.gr](mailto:amilitsi@iee.gr) | [fotkalatzi@iee.gr](mailto:fotkalatzi@iee.gr)



Supported by GSRT funded project "STHENOS-b"





**Institute of Chemical Biology/  
National Hellenic Research Foundation  
Drug Discovery Symposium on**

**“Targeted therapeutic approaches against cancer and aging”**

**Monday 14 June 2021**

<b>Session 1. Chairpersons: Dr E. Gonos (NHRF) - Dr A. Xenakis (NHRF)</b>	
<b>09:00 -09:10</b>	<b>Dr Vasilis Gregoriou (welcome)</b> NHRF Director & Chairman of the Board, Athens, Greece
<b>09:10- 10:20</b>	NHRF/ICB STHENOS-b project outlines
<b>09:10- 09:50</b>	<b>Dr Alex Pintzas, NHRF/ICB, “Drug discovery for targeting cancer drivers”</b>
<b>09:50-10:20</b>	<b>Dr Maria Koufaki, NHRF/ICB, “Targeting proteasome as anti-ageing strategy”</b>
<b>10:20-11:10</b>	<b>Prof Nissim Garti, Hebrew University of Jerusalem, Israel</b> “Novel nano delivery vehicles for cannabinoids for medical applications”
<b>11:10-11:20</b>	Coffee break
<b>Session 2. Chairpersons: Dr T. Calogeropoulou (NHRF)- Dr S. Zografos (NHRF)</b>	
<b>11:20-12:10</b>	<b>Prof. Maria Paola Costi, University of Modena and Reggio Emilia, Italy</b> “Triggering homodimeric protein dissociation for design of anticancer leads”
<b>12:10-13:00</b>	<b>Prof. Stefano Mangani, University of Siena, Siena, Italy</b> “Silencing Thymidylate Synthase, new strategies for an old target”
<b>13: 00-13:20</b>	Light lunch break
<b>Session 3. Chairpersons: Dr N. Chondrogianni (NHRF)- Dr G. Skretas (NHRF)</b>	
<b>13:20-14:10</b>	<b>Prof. Mark Bradley, The University of Edinburgh, Edinburgh, UK</b> “Using Photons to Image and Destroy Cancers”
<b>14:10-15:00</b>	<b>Dr Valerie Vanhooren, CEO ONA Therapeutics, Barcelona, Spain</b> Transforming academic cancer research into a drug: from bench to bedside
<b>15:00-15:10</b>	Coffee break
<b>Session 4. Chairpersons: Dr T. Katsila (NHRF)- Dr P. Georgiadis (NHRF)</b>	
<b>15:10- 16:00</b>	<b>Dr Chris Torrance, CEO, Phoremot Ltd, Cambridgeshire, UK</b> “Drugging the Undruggable with Protein-interference”
<b>16:00-16:50</b>	<b>Dr George N. Pavlakis, National Cancer Institute, Frederick, MD, USA</b> “The promise of cancer immunotherapy”
<b>16:50-17:00</b>	Coffee break

<b>Session 5.</b>	<b>Chairpersons: Dr A. Pintzas (NHRF)- Dr M. Zervou (NHRF)</b>
<b>17:00-17:50</b>	<b>Dr Gideon E. Bollag, CEO, Plexxikon Inc, Berkeley, CA, USA</b> "Structure Guided Strategies to Optimize Cancer Therapies"
<b>17:50-18:40</b>	<b>Prof. Ian Collins, Institute for Cancer Research, London, UK</b> "Design and discovery of selective inhibitors of tumour stress responses"
	<b>Closing remarks</b> Prof Ian Collins, Dr Alex Pintzas, Dr Theodora Calogeropoulou

**National Hellenic Research Foundation (NHRF)**  
**48, Vas. Constantinou Avenue, Athens, Greece**

